Renal Cell Carcinoma

Renal cell carcinoma (RCC, also known as hypernephroma) is a kidney cancer that originates in the lining of the proximal convoluted tubule, the very small tubes in the kidney that filter the blood and remove waste products.

What is Renal Cell Carcinoma?

Renal cell carcinoma, also called hypernephroma, is a cancer of the kidneys that forms in the proximal convoluted tubule. In the UK, it is the eighth most common cancer among adults, affecting 9,300 people every year.

Adjuvant Therapy in Renal Cell Carcinoma

Renal Cell Carcinoma Symptoms

Renal Cell Carcinoma Risk Factors

Renal Cell Carcinoma Treatments

Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma Survival Rate

Renal Cell Carcinoma Epidemiology

Renal Cell Carcinoma Diagnosis

Latest Renal Cell Carcinoma News and Research

New dual drugs eliminate tumors when combined with immunotherapy

Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be "master regulators" of cancer progression.

2 Apr 2026

New computational method links individual cells to patient outcomes

A computational method called scSurv, developed by researchers at Institute of Science Tokyo, links individual cells to patient outcomes using widely available bulk RNA sequencing data.

23 Mar 2026

Minimally invasive ablation effective for early-stage kidney cancers

A large national study in Denmark following nearly 1,900 patients over almost a decade found that a minimally invasive procedure called ablation is as effective as surgery for treating small kidney cancers, with faster recovery and fewer complications. Results of the study were published today in Radiology, a journal of the Radiological Society of North America (RSNA).

3 Mar 2026

A new standard for preventing post-surgery kidney cancer relapse

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when treated with an oral combination regimen that includes belzutifan, a HIF-2α inhibitor, given with standard immune therapy pembrolizumab.

1 Mar 2026

AI-guided discovery of selective DGKα inhibitors to overcome checkpoint resistance in solid cancers

Insilico Medicine has developed a new class of small molecule inhibitors targeting diacylglycerol kinase alpha (DGKα) designed to restore T cell function and overcome resistance to immune checkpoint blockades in solid cancers.

12 Dec 2025

Drug shows striking success in treating children with multi-metastatic Ewing sarcoma

Ewing sarcoma is one of the most common bone cancers seen in children, and if it spreads, it can be deadly. One study found that under a quarter of children with multi-metastatic Ewing sarcoma survived five years after their diagnosis.

23 Oct 2025

Researchers engineer a tool to dismantle cancer's RNA-built growth hubs

In a city, coworking hubs bring people and ideas together. Inside cancer cells, similar hubs form-but instead of fueling progress, they supercharge disease. That's what researchers at the Texas A&M University Health Science Center (Texas A&M Health) have discovered inside the cells of a rare and aggressive kidney cancer.

21 Oct 2025

Belzutifan demonstrates strong clinical activity in two rare neuroendocrine tumors

A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced pheochromocytoma and paraganglioma (PPGL), two rare and potentially life-threatening neuroendocrine tumors.

18 Oct 2025

PRMT5 inhibition induces ferroptosis and enhances immunotherapy efficacy in renal cell carcinoma

Ferroptosis, a regulated cell death mechanism, is emerging as a promising target for cancer therapy. The process is mediated by the activity of acyl-CoA synthetase family member 4 (ACSL4) protein.

22 Sep 2025

New off-the-shelf immunotherapy for metastatic kidney cancer could help improve outcomes

UCLA researchers have developed a new kind of immunotherapy that uses specially engineered immune cells equipped with built-in weapons to attack kidney cancer tumors and reprogram their protective environment - all without the need to customize treatment for each individual patient.

29 Aug 2025

Glycosylation emerges as a key player in kidney disease progression

Kidney diseases affect nearly 700 million people worldwide and are a growing cause of mortality and health care costs.

29 Aug 2025

Engineered CD40 antibody shrinks tumors and induces remission

Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise-and induced great disappointment.

14 Aug 2025

3D-printed kidney tumors offer a new tool in the fight against renal cancer

Scientists at Tsinghua University have developed a method to grow kidney tumors in the lab using cells from real patients, offering a potential new tool in the fight against renal cancer.

12 Aug 2025

HOXB13 emerges as a context-dependent regulator in cancer biology

HOXB13, a B-class homeobox transcription factor, sits at the hub of developmental gene networks yet has emerged as a double-edged sword in human cancer.

5 Aug 2025

Two-drug combo shows durable benefit in advanced kidney cancer

A two-drug combination for treating advanced kidney cancer had sustained and durable clinical benefit in more than five years of follow-up, according to a study published Aug. 1 in Nature Medicine.

1 Aug 2025

Rare kidney cancer evades immune system in unique ways

Cancer fighting T-cells, the immune system's primary enforcers, are scarce in the rare kidney cancer called chromophobe renal cell carcinoma (ChRCC) and those that are present are indifferent to the tumor threat and traditional immune therapies, revealing the need for new targets and treatments.

4 Jul 2025

Navigating the dual role of B cells in tumor immunity

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

3 Jun 2025

MD Anderson researchers present promising clinical trial results at AACR 2025

Researchers from The University of Texas MD Anderson Cancer Center will present promising results from clinical trials in three minisymposia abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2025.

26 Apr 2025

Do lifetime body weight patterns affect kidney cancer risk?

Excess weight in mid-life is a known risk factor for kidney cancer, but new research indicates that weight patterns throughout life may also affect an individual’s likelihood of developing this malignancy.

1 Apr 2025

Waist circumference identified as a stronger cancer risk marker in men

Body size and excess weight, conventionally assessed using body mass index (BMI), are well-established risk factors for many types of cancer. However, new research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) and published in The Journal of the National Cancer Institute shows that waist circumference (WC) is a stronger risk marker than BMI for developing obesity-related cancers in men, but not women.

24 Mar 2025